


PHARMACEUTICAL 2022











PHARMACEUTICAL 2022



Zomedica Corp. Rank 12 of 466



The relative strengths and weaknesses of Zomedica Corp. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Zomedica Corp. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 53% points. The greatest weakness of Zomedica Corp. is the variable Other Revenues, reducing the Economic Capital Ratio by 11% points.

The company's Economic Capital Ratio, given in the ranking table, is 308%, being 230% points above the market average of 78%.

| Input Variable | Value in 1000 USD |
|---|----------------------|
| Assets, Current | 200,408 |
| Cost of Goods Sold | 1,079 |
| Intangible Assets | 76,807 |
| Liabilities, Current | 4,340 |
| Liabilities, Non-Current | 1,465 |
| Other Assets | 1,979 |
| Other Compr. Net Income | -1.7 |
| Other Expenses | -2,321 |
| Other Liabilities | 3,709 |
| Other Net Income | -403 |
| Other Revenues | 4,133 |
| Property and Equipment | 1,206 |
| Research and Development | 1,673 |
| Selling, General and Administrative Expense | 22,749 |

| Output Variable | Value in 1000 USD |
|--------------------------|----------------------|
| Assets | 280,399 |
| Liabilities | 9,514 |
| Expenses | 23,180 |
| Revenues | 4,133 |
| Stockholders Equity | 270,885 |
| Net Income | -19,450 |
| Comprehensive Net Income | -19,451 |
| Economic Capital Ratio | 308% |

